| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Over the last 12 months, insiders at Aclaris Therapeutics, Inc. have bought $0 and sold $0 worth of Aclaris Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aclaris Therapeutics, Inc. have bought $3.69M and sold $8.65M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 666,666 shares for transaction amount of $1.5M was made by Mehra Anand (director) on 2024‑11‑19.
| 2024-11-19 | Mehra Anand | director | 666,666 0.4477% | $2.25 | $1.5M | -59.91% | ||
| 2024-08-05 | Leonard Braden Michael | 10 percent owner | 206,025 0.2901% | $1.24 | $256,357 | +24.60% | ||
| 2024-08-02 | Leonard Braden Michael | 10 percent owner | 167,544 0.2372% | $1.29 | $216,400 | +20.31% | ||
| 2024-07-31 | Leonard Braden Michael | 10 percent owner | 100,000 0.1421% | $1.33 | $132,640 | +14.55% | ||
| 2024-07-30 | Leonard Braden Michael | 10 percent owner | 173,730 0.2425% | $1.30 | $226,370 | +17.18% | ||
| 2024-07-22 | Leonard Braden Michael | 10 percent owner | 17,716 0.0249% | $1.33 | $23,557 | +13.91% | ||
| 2024-07-19 | Leonard Braden Michael | 10 percent owner | 6,689 0.0092% | $1.30 | $8,696 | +12.88% | ||
| 2024-07-18 | Leonard Braden Michael | 10 percent owner | 130,317 0.1816% | $1.30 | $169,555 | +13.74% | ||
| 2024-07-05 | Leonard Braden Michael | 10 percent owner | 123,017 0.1779% | $1.15 | $141,334 | +20.83% | ||
| 2024-07-03 | Leonard Braden Michael | 10 percent owner | 143,288 0.209% | $1.16 | $166,071 | +26.09% | ||
| 2024-07-02 | Leonard Braden Michael | 10 percent owner | 86,092 0.1239% | $1.14 | $98,489 | +27.19% | ||
| 2024-07-01 | Leonard Braden Michael | 10 percent owner | 107,434 0.1538% | $1.14 | $122,185 | +25.65% | ||
| 2024-06-28 | Leonard Braden Michael | 10 percent owner | 1.2M 1.6972% | $1.12 | $1.35M | +31.82% | ||
| 2024-06-27 | Leonard Braden Michael | 10 percent owner | 235,000 0.3415% | $1.15 | $271,331 | +30.18% | ||
| 2024-06-18 | Leonard Braden Michael | 10 percent owner | 50,000 0.0708% | $1.13 | $56,505 | +24.34% | ||
| 2024-06-17 | Leonard Braden Michael | 10 percent owner | 150,000 0.2124% | $1.13 | $169,500 | +23.89% | ||
| 2024-06-14 | Leonard Braden Michael | 10 percent owner | 345,000 0.5039% | $1.17 | $402,201 | +18.64% | ||
| 2024-06-13 | Leonard Braden Michael | 10 percent owner | 528,621 0.7614% | $1.15 | $607,757 | +17.23% | ||
| 2024-06-12 | Leonard Braden Michael | 10 percent owner | 82,579 0.1179% | $1.14 | $94,140 | +20.43% | ||
| 2024-06-11 | Leonard Braden Michael | 10 percent owner | 1M 1.3531% | $1.08 | $1.08M | +23.21% |
| Leonard Braden Michael | 10 percent owner | 14250000 13.1524% | $45.46M | 19 | 0 | +21.4% |
| CHA ALBERT | director | 4191397 3.8686% | $13.37M | 2 | 0 | +71.55% |
| FMR LLC | 10 percent owner | 2571354 2.3733% | $8.2M | 1 | 1 | +61.56% |
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2289480 2.1131% | $7.3M | 1 | 0 | +61.56% |
| RA CAPITAL MANAGEMENT, LLC | 10 percent owner | 2102169 1.9403% | $6.71M | 17 | 2 | +27.75% |
| Walker Neal | director | 1273202 1.1751% | $4.06M | 1 | 11 | <0.0001% |
| Flynn James E | 10 percent owner | 964101 0.8898% | $3.08M | 0 | 7 | |
| Mehra Anand | director | 710030 0.6553% | $2.26M | 3 | 1 | <0.0001% |
| SCHIFF ANDREW N | director | 434455 0.401% | $1.39M | 1 | 12 | <0.0001% |
| Ruffo Frank | Chief Financial Officer | 201883 0.1863% | $644,006.77 | 2 | 6 | <0.0001% |
| Tullman Stephen A. | director | 177457 0.1638% | $566,087.83 | 4 | 0 | <0.0001% |
| Gordon David N. | Chief Medical Officer | 147447 0.1361% | $470,355.93 | 0 | 3 | |
| Monahan Joseph | Chief Scientific Officer | 129724 0.1197% | $413,819.56 | 0 | 12 | |
| Ali-Jackson Kamil | Chief Legal Officer | 122196 0.1128% | $389,805.24 | 0 | 14 | |
| VIVO VENTURES VII, LLC | 10 percent owner | 60972 0.0563% | $194,500.68 | 2 | 5 | +71.55% |
| Powell Andrew Kenneth William | director | 28863 0.0266% | $92,072.97 | 3 | 0 | <0.0001% |
| Loerop James | Chief Business Officer | 21688 0.02% | $69,184.72 | 1 | 1 | |
| Balthaser Kevin | Chief Financial Officer | 15461 0.0143% | $49,320.59 | 1 | 2 | |
| Manion Douglas J. | Pres and CEO | 12800 0.0118% | $40,832.00 | 2 | 0 | |
| Molineaux Christopher P. | director | 7682 0.0071% | $24,505.58 | 0 | 1 |
| Increased Positions | 52 | +49.06% | 8M | +8.42% |
| Decreased Positions | 43 | -40.57% | 11M | -12.38% |
| New Positions | 20 | New | 3M | New |
| Sold Out Positions | 6 | Sold Out | 859,633 | Sold Out |
| Total Postitions | 115 | +8.49% | 88M | -3.96% |
| Bml Capital Management, Llc | $41,040.00 | 13.19% | 14.25M | 0 | 0% | 2025-09-30 |
| Vivo Capital, Llc | $25,600.00 | 8.23% | 8.89M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $18,765.00 | 6.03% | 6.52M | -146,605 | -2.2% | 2025-09-30 |
| Blackrock, Inc. | $16,391.00 | 5.27% | 5.69M | +176,473 | +3.2% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $15,201.00 | 4.89% | 5.28M | -4M | -45.17% | 2025-09-30 |
| Rock Springs Capital Management Lp | $13,275.00 | 4.27% | 4.61M | -160,000 | -3.35% | 2025-09-30 |
| Morgan Stanley | $11,742.00 | 3.78% | 4.08M | +537,054 | +15.17% | 2025-09-30 |
| Decheng Capital Llc | $11,640.00 | 3.74% | 4.04M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $6,882.00 | 2.21% | 2.39M | -75,248 | -3.05% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $6,835.00 | 2.2% | 2.37M | -427,056 | -15.25% | 2025-09-30 |